Contact

Guide your clinical trials
to success

We are committed to improving patient outcomes and reducing human suffering through AI-driven Foundation Models, custom-built to reshape drug development  
Get in touch

What we do

NUMENOS was inspired by the opportunity to unlock new possibilities in drug development. We experienced the limitations of traditional methods and we knew we could do better for patients.

Faster trials

Allow faster Trials with a Priority Review Vouchers (PRV) like effect

Drug differentiation

Detect unmet medical need (compared to SOC)

Multi - indication

Prioritize assets relevant to multiple indication

Target discovery

Allow biomarker driven target discovery - concentrated on unmet need population

Proper model selection

Select biomarker positive model systems

Bio - Sample prioritization

Know which samples should be analyzed to bring maximum value

Our approach

CURE Is Designed To Maximize Data Value, By Revealing Drug Benefits

C
Click here

Clinical trials

The CURE platform integrates & analyzes RWD and Phase I-IV clinical data, revealing valuable insights to guide data-driven decision-making & patient stratification and reverse translation target discovery.

Contact us
U
Click here

Uncovering

The platform leverages a proprietary, integrated, and interpretable foundation model with over 100 million parameters to unravel causal and predictive biomarkers
and targets.
Contact us
R
Click here

Real

Platform unravels the real benefit of experimental drug compared to SOC on an individual patient level.

Contact us
E
Click here

Efficacy

Platform reveals molecular fingerprints of patients most likely to benefit from a given therapy, revealing disease mechanism(s).
Contact us

Value of CURE individualized medicine approach

Get in touch

Earlier success

Patient enrichment lead to earlier success signal in a "PRV like" effect

Avoiding defeats

Revealing disease progression mechanisms (s) & biological mechanism(s) behind drug benefit.

Biomarker driven

Biomarker driven reverse and forward translation (clinically driven target discovery)

Significance boost

Average 10x increase in trial significance (including trial rescue from failure).

Novel mechanisms

Novel disease mechanism(s) using WES, metabolomics or RNASeq.

Trial reduction

50%-70% reduction in trial size

About us

We are a group of entrepreneurs, biologists, physicists and AI specialists, with vast experience in AI, Pharma, R&D, target discovery, clinical trial and biomarker strategy development. 

Vitalay Fomin, Ph.D. Co-founder & CEO

  • Bridging biology & tech for innovative solutions
  • Biomarker discovery & translational medicine
  • Data science & Biomarker discovery in Oncology
  • Biomarker innovation award winner & patent co-athor in ML-based biomarker discovery

Amit Weiss, M.Sc. Co-founder & CTO

  • Talpiot alumni and former physicist with over a decade of AI experience
  • Led cutting-edge R&D projects across multiple domains
  • Pioneered novel solutions in machine learning and deep learning
  • Hands-on technical leadership, bridging theory and practice

Deep Tech and Biopharma Experts To Solve Problems That Matter

Cameron Durrant , MD, MPH (5x CEO)
Biotech & BD
Ofir Levi, PhD
Biotech & BD
Moran Cabili, PhD
Science
John Blumenthal
AI Infrastructure & BD
Neil Pfister, MD, PhD
Science
Frank Chavez
Biotech & BD

Clinical trial data can trasform all steps in drug development

Contact us

Vision

Clinical trial data is the highest quality data with most the value & potential.

Challenge

Limited sample size & high of clinical data limit ML/AI applicability resulting in lost potential

Solution

Causal foundation model solves dimensionality & uncovers data potential providing transformative value

Start a transformational journey with a Numenos that values innovation, collaboration, and excellence.

"*" indicates required fields

info@numenos.ai

©2024 NUMENOS. All rights reserved